Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999-2008 National Health and Nutrition Examination Surveys

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Tattersall, Matthew C ^a   Gangnon, Ronald E ^a   Karmali, Kunal N ^a   Cullen, Michael W ^b   Stein, James H ^a   Keevil, Jon G ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PATIENT SELECTION; POPULATION RISK; RISK ASSESSMENT; TREND STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUTRITION SURVEYS; POPULATION SURVEILLANCE; PREVALENCE; REFERENCE VALUES; RISK; UNITED STATES; YOUNG ADULT;

EID: 84875660326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059309     Document Type: Article

References (42)

1. NCEP Expert Panel, (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237-1245.
3. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
4. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585-1591.
5. O'Leary DH, Polak JF, (2002) Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 90: 18L-21L.
6. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22.
7. Heart Protection Study Collaborative Group (2003) Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016.
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495-1504.
9. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151-1157.
10. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, et al. (2004) Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93: 154-158.
11. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98: 2513-2519.
12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720-732.
13. NCEP Expert Panel, (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269: 3015-3023.
14. Cullen MW, Stein JH, Gangnon R, McBride PE, Keevil JG, (2008) National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart J 156: 284-291.
15. Ghandehari H, Kamal-Bahl S, Wong ND, (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in U.S. adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 156: 112-119.
16. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681.
17. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, et al. (2005) Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96: 556-563.
18. Kuklina EV, Yoon PW, Keenan NL, (2009) Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 302: 2104-2110.
19. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11: 1-190.
20. Flegal KM, Carroll MD, Ogden CL, Curtin LR, (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303: 235-241.
21. Ford ES, Giles WH, Mokdad AH, (2004) Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 27: 2444-2449.
22. Michos ED, Blumenthal RS, (2009) Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 53: 931-935.
23. Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, et al. (2008) A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med 149: 170-176.
24. Sundquist J, Winkleby MA, Pudaric S, (2001) Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 49: 109-116.
25. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, et al. (2004) Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. Am J Epidemiol 160: 531-539.
26. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, et al. (2002) A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 136: 565-574.
27. Ford ES, Giles WH, Mokdad AH, (2004) The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 43: 1791-1796.
28. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375.
29. Friedewald WT, Levy RI, Fredrickson DS, (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
30. Fedder DO, Koro CE, L'Italien GJ, (2002) New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 105: 152-156.
31. Centers for Disease Control and Prevention (2005) National Health and Nutrition Examination Survey (NHANES) analytic and reporting guidelines. Hyattsville, Maryland: National Center for Health Statistics.
32. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J, (1998) Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82: 61-65.
33. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, et al. (2000) Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med 160: 1361-1369.
34. Case CC, Jacobson TA, Roberts S, Buckley A, Murtaugh KM, et al. (2003) Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol 91: 1134-1136.
35. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL, (1998) Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 158: 1238-1244.
36. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, et al. (2009) Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28-34.
37. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG, (2005) The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 28: 1029-1034.
38. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, et al. (2004) Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 27: 694-698.
39. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, et al. (2001) Clinical inertia. Ann Intern Med 135: 825-834.
40. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, et al. (2006) Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 19: 46-53.
41. Amarenco P, Labreuche J, Lavallee P, Touboul PJ, (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902-2909.
42. Amarenco P, Labreuche J, (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8: 453-463.